Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:March 1, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Multiple Myeloma in RelapseLast Updated:March 1, 2023Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:March 27, 2024Recruiting
Condition(s):Multiple MyelomaLast Updated:April 3, 2020Completed
Condition(s):Multiple MyelomaLast Updated:March 13, 2024Active, not recruiting
Condition(s):Multiple MyelomaLast Updated:January 2, 2024Not yet recruiting
Condition(s):Myeloma Multiple; Myeloma, Plasma-Cell; Myeloma-Multiple; Plasma Cell MyelomaLast Updated:January 27, 2022Completed
Condition(s):High-risk Smoldering Multiple Myeloma; Multiple MyelomaLast Updated:September 21, 2023Recruiting
Condition(s):Multiple MyelomaLast Updated:March 28, 2024Active, not recruiting
Condition(s):Relapse and / or Refractory MyelomaLast Updated:June 7, 2018Unknown status
Condition(s):Multiple Myeloma in Relapse; Refractory Multiple MyelomaLast Updated:April 21, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.